QUANTIFICATION OF RECEPTOR INTERACTIONS USING BINDING METHODS

REFERENCES

• Yamamura H. I., Enna S. J., Kuhar M. H. Neurotransmitter Receptor Binding. Raven Press, New York 1978
   Google Scholar
• Nahorski S. R. What are the Criteria in Ligand-Binding Studies for Use in Receptor Classification?. Perspectives on Receptor Classification, J. W. Black, D. H. Jenkinson, V. P. Gerskowitch. Alan R Liss, New York 1987; 51–59
   Google Scholar
• Yamamura H. I., Enna S. J., Kuhar M. H. Methods in Neurotransmitter Receptor Analysis. Raven Press, New York 1978
   Google Scholar
• Hulme E. C. Receptor–Ligand Interactions: A Practical Approach. Oxford University Press, Oxford 1992
   Google Scholar
• Hulme E. C., Birdsall N. J.M. Strategy and Tactics in Receptor-Binding Studies. Receptor – Ligand Interactions: A Practical Approach, E. C. Hulme. Oxford University Press, Oxford 1992; 63–176
   Google Scholar
• Bylund D. B., Toews M. L. Radioligand-Binding Methods: Practical Guide and Tips. Am. J. Physiol. 1993; 265: L421–L429
   Google Scholar
• Lauffenburger D. A., Linderman J. J. Receptors: Models for Binding, Trafficking, and Signalling. Oxford University Press, New York 1993
   Google Scholar
• Keen M. The Problems and Pitfalls of Radioligand-Binding. Methods in Molecular Biology: Signal Transduction Protocols, D. A. Kendall, S. J. Hill. Humana Press, Totawa, NJ 1995; 41: 1–16
   Google Scholar
• Motulsky H., Analysing Radioligand-Binding Data. Available on the Internet: http://www.graphpad.com, 1995
   Google Scholar
• Limbird L. E. Cell Surface Receptors: A Short Course on Theory and Methods. 2nd Ed., Kluwer Academic Publishers, Boston 1996
   Google Scholar
• Cheng Y., Prusoff W. H. Relationship Between the Inhibition Constant (Ki) and the Concentration of an Inhibitor Which Causes 50 per cent Inhibition (I50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973; 22: 3099–3108
   PubMed Web of Science ®Google Scholar
• Waelbroeck M., Tastenoy M., Camus J., Christophe J. Binding Kinetics of Quinuclidinyl Benzilate and Methyl-Quinuclidinyl Benzilate Enantiomers at Neuronal (M1), Cardiac (M2), and Pancreatic (M3) Muscarinic Receptors. Mol. Pharmacol. 1991; 40: 413–420
   PubMedGoogle Scholar
• Motulsky H. J., Mahan L. C. The Kinetics of Competitive Radioligand-Binding Predicted by the Law of Mass Action. Mol. Pharmacol. 1984; 25: 1–9
   PubMed Web of Science ®Google Scholar
• Koenig J. A., Edwardson J. M. Intracellular Trafficking of the Muscarinic Acetylcholine Receptor: Importance of Subtype and Cell Type. Mol. Pharmacol. 1996; 49: 351–359
   PubMed Web of Science ®Google Scholar
• Lazareno S., Nahorski S. R. Errors in Kd Estimates Related to Tissue Concentration in Ligand-Binding Assays Using Filtration. Br. J. Pharmacol. 1982; 77: 571P, (abstract)
   Google Scholar
• Hulme E. C. Gel-Filtration Sssays for Solubilised Receptors. Receptor–Ligand Interactions: A Practical Approach, E. C. Hulme. Oxford University Press, Oxford 1992; 255–263
   Google Scholar
• Bennett J. P., Jr. Methods in Binding Studies. Neurotransmitter Receptor Binding, H. I. Yamamura, S. J. Enna, M. H. Kuhar. Raven Press, New York 1978; 57–90
   Google Scholar
• Wang J.-X., Yamamura H. I., Wang W., Roeske W. R. The Use of the Filtration Technique in in vitro Radioligand-Binding Assays for Membrane Bound and Solubilized Receptors. Receptor–Ligand Interactions: A Practical Approach, E. C. Hulme. Oxford University Press, Oxford 1992
   Google Scholar
• Hulme E. C. Centrifugation Binding Assays. Receptor–Ligand Interactions: A Practical Approach, E. C. Hulme. Oxford University Press, Oxford 1992; 235–246
   Google Scholar
• Cohen F. R., Lazareno S., Birdsall N. J.M. The Effects of Saponin on the Binding and Functional Properties of the Human Adenosine A1 Receptor. Br. J. Pharmacol. 1996; 117: 1521–1529
   PubMedGoogle Scholar
• Koenig J. A., Edwardson J. M., Humphrey P. P.A. Somatostatin Receptors in Neuro2A Neuroblastoma Cells: Operational Characteristics. Br. J. Pharmacol. 1997; 120: 45–51
   PubMedGoogle Scholar
• Giles H., Landsdell S. J., Bolofo M. L., Wilson H. L., Martin G. R. Characterization of a 5-HT(1B) Receptor on CHO Cells: Functional Responses in the Absence of Radioligand-Binding. Br. J. Pharmacol. 1996; 117: 1119–1126
   PubMedGoogle Scholar
• Clarke P. B.S. Recent Progress in Identifying Nicotinic Receptors in Mammalian Brain. Trends Pharmacol. Sci. 1997; 8: 32–35
   Google Scholar
• Quik M., Babu U., Audhya T., Goldstein G. Evidence for Thymopoietin and Thymopoietin/alpha-Bungarotoxin/Nicotinic Receptors within the Brain. Proc. Natl. Acad. Sci. 1991; 88: 2603–2607, [retracted by Venkatasubramanian, K., Audhya, T., Goldstein, G., Revah, F., Mulle, C., Pinset, C., Changeux, J.P., Quik, M., Babu, U. In: Proc. Natl. Acad. Sci. USA 1993 90 (21), 10409]. USA
   PubMedGoogle Scholar
• McGehee D. S., Role L. W. Physiological Diversity of Nicotinic Acetylcholine Receptors Expressed by Vertebrate Neurons. Annu. Rev. Physiol. 1995; 57: 521–546
   PubMed Web of Science ®Google Scholar
• Quik M., Cook R. G., Revah F., Changeux J. P., Patrick J. Presence of Alpha-Cobratoxin and Phospholipase A2 Activity in Thymopoietin Preparations. Mol. Pharmacol. 1993; 44: 678–679
   PubMedGoogle Scholar
• Cuatrecasas P., Hollenberg M. D. Binding of Insulin and Other Hormones to Non-Receptor Materials: Saturability, Specificity and Apparent “Negative Cooperativity.”. Biochem. Biophys. Res. Commun. 1975; 62: 31–41
   PubMedGoogle Scholar
• Snyder S. H. Overview of Neurotransmitter Receptor Binding. Neurotransmitter Receptor Binding, H. I. Yamamura, S. J. Enna, M. H. Kuhar. Raven Press, New York 1978; 1–11
   Google Scholar
• Munson P. J., Rodbard D. LIGAND: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems. Anal. Biochem. 1980; 107: 220–239
   PubMed Web of Science ®Google Scholar
• Swillens S. Interpretation of Binding Curves Obtained with High Receptor Concentrations: Practical Aid for Computer Analysis. Mol. Pharmacol. 1995; 47: 1197–1203
   PubMed Web of Science ®Google Scholar
• Leeb-Lundberg L. M., Mathis S. A. Guanine Nucleotide Regulation of B2 Kinin Receptors. Time-Dependent Formation of a Guanine Nucleotide-Sensitive Receptor State from Which [3H]bradykinin Dissociates Slowly. J. Biol. Chem. 1990; 265: 9621–9627
   PubMedGoogle Scholar
• De Lean A., Stadel J. M., Lefkowitz R. J. A Ternary Complex Model Explains the Agonist-Specific Binding Properties of the Adenylate Cyclase-Coupled Beta-adrenergic Receptor. J. Biol. Chem. 1980; 255: 7108–7117
   PubMed Web of Science ®Google Scholar
• Samama P., Cotecchia S., Costa T., Lefkowitz R. J. A Mutation-Induced Activated State of the Beta 2-adrenergic Receptor. Extending the Ternary Complex Model. J. Biol. Chem. 1993; 268: 4625–4636
   PubMed Web of Science ®Google Scholar
• Tota M. R., Schimerlik M. I. Partial Agonist Effects on the Interaction Between the Atrial Muscarinic Receptor and the Inhibitory Guanine Nucleotide-Binding Protein in a Reconstituted System. Mol. Pharmacol. 1990; 37: 996–1004
   PubMedGoogle Scholar
• Ehlert F. J. The Relationship Between Muscarinic Receptor Occupancy and Adenylate Cyclase Inhibition in the Rabbit Myocardium. Mol. Pharmacol. 1985; 28: 410–421
   PubMed Web of Science ®Google Scholar
• Lee T. W., Sole M. J., Wells J. W. Assessment of a Ternary Model for the Binding of Agonists to Neurohumoral Receptors. Biochemistry 1986; 25: 7009–7020
   PubMedGoogle Scholar
• Page K. M., Curtis C. A., Jones P. G., Hulme E. C. The Functional Role of the Binding site Aspartate in Muscarinic Acetylcholine Receptors, Probed by Site-Directed Mutagenesis. Eur. J. Pharmacol. 1995; 289: 429–437
   PubMedGoogle Scholar
• Sibley D. R., Creese I. Interactions of Ergot Alkaloids with Anterior Pituitary D-2 Dopamine Receptors. Mol. Pharmacol. 1983; 23: 585–593
   PubMedGoogle Scholar
• van Rampelbergh J., Gourlet P., de Neef P., Robberecht P., Waelbroeck M. Properties of the Pituitary Adenylate Cyclase-Activating Polypeptide I and II Receptors, Vasoactive Intestinal Peptide, and Chimeric Amino-Terminal Pituitary Adenylate Cyclase-Activating Polypeptide/Vasoactive Intestinal Peptide1 Receptors: Evidence for Multiple Receptor States. Mol. Pharmacol. 1996; 50: 1596–1604
   PubMed Web of Science ®Google Scholar
• Schutz W., Freissmuth M. Reverse Intrinsic Activity of Antagonists on G Protein-Coupled Receptors. Trends Pharmacol. Sci. 1992; 13: 376–380
   PubMed Web of Science ®Google Scholar
• Leeb Lundberg L. M., Mathis S. A., Herzig M. C. Antagonists of Bradykinin that Stabilize a G-Protein-Uncoupled State of the B2 Receptor Act as Inverse Agonists in Rat Myometrial Cells. J. Biol. Chem. 1994; 269: 25970–25973
   PubMedGoogle Scholar
• Hilf G., Jakobs K. H. Agonist-Independent Inhibition of G Protein Activation by Muscarinic Acetylcholine Receptor Antagonists in Cardiac Membranes. Eur. J. Pharmacol. 1992; 225: 245–252
   PubMedGoogle Scholar
• Barker E. L., Westphal R. S., Schmidt D., Sanders Bush E. Constitutively Active 5-hydroxytryptamine 2C Receptors Reveal Novel Inverse Agonist Activity of Receptor Ligands. J. Biol. Chem. 1994; 269: 11687–11690
   PubMed Web of Science ®Google Scholar
• Bond R. A., Leff P., Johnson T. D., Milano C. A., Rockman H. A., McMinn T. R., Apparsundaram S., Hyek M. F., Kenakin T. P., Alien L. F., et al. Physiological Effects of Inverse Agonists in Transgenic Mice with Myocardial Overexpression of the Beta 2-adrenoceptor. Nature 1995; 374: 272–276
   PubMed Web of Science ®Google Scholar
• Kenakin T. The Classification of Seven Transmembrane Receptors in Recombinant Expression Systems. Pharmacol. Rev. 1996; 48: 413–451
   PubMed Web of Science ®Google Scholar
• Kenakin T. Receptor Conformational Induction Versus Selection: All Part of the Same Energy Landscape. Trends Pharmacol. Sci. 1996; 17: 190–191
   Web of Science ®Google Scholar
• Burstein E. S., Spalding T. A., Brauner Osborne H., Brann M. R. Constitutive Activation of Muscarinic receptors by the G-protein Gq. FEBS Lett. 1995; 363: 261–263
   PubMedGoogle Scholar
• Colquhoun D. Affinity, Efficacy, and Receptor Classification: Is the Classical Theory Still Useful?. Perspectives on Receptor Classification, J. W. Black, D. H. Jenkinson, V. P. Gerskowitch. Alan R Liss, New York 1987; 103–114
   Google Scholar
• Samama P., Pei G., Costa T., Cotecchia S., Lefkowitz R. J. Negative Antagonists Promote an Inactive Conformation of the Beta 2-adrenergic Receptor. Mol. Pharmacol. 1994; 45: 390–394
   PubMed Web of Science ®Google Scholar
• Perez D. M., Hwa J., Gaivin R., Mathur M., Brown F., Graham R. M. Constitutive Activation of a Single Effector Pathway: Evidence for Multiple Activation States of a G Protein-Coupled Receptor. Mol. Pharmacol. 1996; 49: 112–122
   PubMed Web of Science ®Google Scholar
• Onaran H. O., Costa T., Rodbard D. Beta Gamma Subunits of Guanine Nucleotide-Binding Proteins and Regulation of Spontaneous Receptor Activity: Thermodynamic Model for the Interaction Between Receptors and Guanine Nucleotide-Binding Protein Subunits. Mol. Pharmacol. 1993; 43: 245–256
   PubMedGoogle Scholar